Editas Medicine (EDIT) reported new positive data from the phase I/II/III RUBY study of its lead candidate, reni-cel, in 18 patients with sickle cell disease (SCD) and the phase I/II EdiTHAL study of the same in seven patients with transfusion-dependent beta thalassemia (TDT) in separate press releases. The company is focused on developing reni-cel as a potential one-time, durable gene editing medicine to treat these indications. This data readout follows the December 2023 press release, when the company la ...